- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03170609
A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age
June 13, 2019 updated by: Pfizer
A PHASE 1/2, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY ADULTS 18 TO 49 YEARS OF AGE
This is the Phase 1/2 first-in-human, randomized, placebo-controlled, observer-blinded study evaluating the investigational multivalent group B streptococcus vaccine.
Healthy adults aged 18 to 49 years of age with no history of group B streptococcal vaccination will be randomized to receive either a single intramuscular dose of multivalent group B streptococcus vaccine (various formulations at 3 dose levels) or a placebo (saline control).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
365
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Georgia
-
Stockbridge, Georgia, United States, 30281
- Clinical Research Atlanta
-
-
Kentucky
-
Bardstown, Kentucky, United States, 40004
- Kentucky Pediatric / Adult Research
-
-
Utah
-
Salt Lake City, Utah, United States, 84109
- J. Lewis Research, Inc. / Foothill Family Clinic
-
Salt Lake City, Utah, United States, 84121
- J. Lewis Research, Inc. / Foothill Family Clinic South
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 49 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy adults (male and female) 18 to 49 years of age at enrollment who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.
- Negative urine pregnancy test at Visit 1 for all female subjects who are of childbearing potential.
Exclusion Criteria:
- Male subjects and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for at least 3 months after the last dose of investigational product.
- Acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study. Chronic medical conditions include human immunodeficiency virus, chronic hepatitis B virus (HBV) infection (HBV surface antigen positive), and/or hepatitis C virus infection.
- History of severe adverse reaction and/or severe allergic reaction (eg, anaphylaxis) to any vaccine.
- History of microbiologically proven invasive disease caused by group B streptococcus (Streptococcus agalactiae).
- Previous vaccination with any licensed or investigational group B streptococcus vaccine, or planned receipt during the subject's participation in the study (through the last blood draw).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lowest dose formulation a
Multivalent group B streptococcus vaccine
|
Various formulations at three dose levels
|
Experimental: Middle dose formulation a
Multivalent group B streptococcus vaccine
|
Various formulations at three dose levels
|
Experimental: Highest dose formulation a
Multivalent group B streptococcus vaccine
|
Various formulations at three dose levels
|
Experimental: Lowest dose formulation b
Multivalent group B streptococcus vaccine
|
Various formulations at three dose levels
|
Experimental: Middle dose formulation b
Multivalent group B streptococcus vaccine
|
Various formulations at three dose levels
|
Experimental: Highest dose formulation b
Multivalent group B streptococcus vaccine
|
Various formulations at three dose levels
|
Placebo Comparator: Placebo
Saline control
|
Saline Control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Clinical Laboratory Abnormalities at 1-Week After Vaccination as Measured by Food and Drug Administration (FDA) Grade
Time Frame: 1 week after vaccination
|
Hemoglobin:Grade(G)1: 11-13.5g/dL,
G2:9.5-12.4g/dL,G3:8-10.4
g/dL, G4:<8.0 g/dL; leukocyte increase:G1: 10.8-15*10^9/Liter[L],G2:>15-20*10^9/L, G3:>20-25*10^9/L, G4:>25*10^9/L,leukocyte decrease: G1: 2.5-3.5*10^9/L,
G2: 1.5-<2.5*10^9/L,
G3: 1-<1.5*10^9/L,
G4:<1*10^9/L; neutrophil decrease:G1: 1.5-2*10^9/L, G2:1-<1.5*10^9/L,
G3:0.5-<1*10^9/L,G4:<0.5*10^9/L;
platelets:G1: 125-140*10^9/L, G2:100-124*10^9/L, G3:25-99*10^9/L, G4:<25*10^9/L; eosinophils: G1: 0.65-1.5*10^9/L,
G2:>1.5-5*10^9/L,
G3:>5*10^9/L, G4: hypereosinophilic;alanine aminotransferase,aspartate aminotransferase:G1: 1.1-2.5 *ULN, G2:2.6-5.0*ULN,
G3:5.1-10*ULN,
G4:>10*ULN; alkaline phosphatase:G1: 1.1-2*ULN, G2:2.1-3*ULN,
G3:3.1-10*ULN,
G4:>10*ULN; Bilirubin:G1: 1.1-1.5*ULN,
G2: 1.26-2*ULN,G3: 1.51-3.0*ULN,G4:>1.75*ULN;blood
urea nitrogen:G1:23-26mg/dL,G2:27-31mg/dL,G3:>31mg/dL, G4:dialysis;creatinine:G1:1.5-1.7mg/dL,G2:1.8-2mg/dL,G3:2.1-2.5 mg/dL,G4:dialysis.Categories with>=1 participant with abnormality are reported only.
|
1 week after vaccination
|
Percentage of Participants With Local Reactions by Maximum Severity Within 14 Days After Vaccination
Time Frame: Within 14 days after vaccination
|
Local reactions were collected by using an e-diary and included redness, swelling and pain at injection site.
Redness and swelling were graded as: mild (2.5-5.0 centimeter [cm]), moderate (greater than [>] 5.0-10.0
cm) and severe (>10.0 cm), grade 4 for redness (necrosis or exfoliative dermatitis) and grade 4 for swelling (necrosis).
Pain at injection site was graded as: mild (did not interfere with activity), moderate (repeated use of nonnarcotic pain reliever >24 hours or interfered with activity), severe (any use of narcotic pain reliever or prevented daily activity which resulted in missed days of work or school or was otherwise incapacitating, or included use of narcotics for analgesia), and grade 4 (required emergency room visit or hospitalization).
The maximum severity (highest grading) of each location reaction within 14 days of vaccination was derived.
|
Within 14 days after vaccination
|
Percentage of Participants With Systemic Events by Maximum Severity Within 14 Days After Vaccination
Time Frame: Within 14 days after vaccination
|
Fever:38.0-38.4
degree Celsius (C),38.5-38.9
degree C,39.0-40.0
degree C,>40.0 degree C;nausea/vomiting:mild(not interfered with activity/1-2times in 24 hours[hr]),moderate(some interference with activity/>2times in 24hr),severe(prevented daily activity;required intravenous hydration); diarrhea:mild(2-3 loose stools in 24hr),moderate(4-5 loose stools in 24hr),severe(>=6 loose stools in 24 hr); headache:mild(not interfered with activity),moderate(repeated use of non-narcotic pain reliever >24 hr/some interference with activity),severe(significant;any use of narcotic pain reliever/prevented daily activity);fatigue,muscle and joint pain:mild(not interfered with activity), moderate(some interference with activity),severe(significant;prevented daily activity).Prevented daily activity=missed days of work, school/otherwise incapacitating/use of narcotics for analgesia.Nausea/vomiting,diarrhea,headache,fatigue/tiredness,muscle and joint pain: grade 4=emergency room visit or hospitalization.
|
Within 14 days after vaccination
|
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination
Time Frame: Within 1 month after vaccination
|
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.
Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.
AEs included both non-serious AEs and SAEs.
|
Within 1 month after vaccination
|
Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Month After Vaccination
Time Frame: Within 6 months after vaccination
|
An AE was any untoward medical occurrence in a participant in a participant who received investigational product without regard to possibility of causal relationship.
SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.
|
Within 6 months after vaccination
|
Percentage of Participants With Medically Attended Adverse Events (MAEs) Within 6 Months After Vaccination
Time Frame: Within 6 months after vaccination
|
An AE was any untoward medical occurrence in a participant in a participant who received investigational product without regard to possibility of causal relationship.
SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.
An MAE was defined as a non serious AE (AE other than SAE) that resulted in an evaluation at a medical facility.
|
Within 6 months after vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GBS6 Serotype-Specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at 1 Month After Vaccination
Time Frame: 1 month after vaccination
|
Serotypes used for evaluation were: Ia, Ib, II, III, IV, and V.
|
1 month after vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 5, 2017
Primary Completion (Actual)
June 25, 2018
Study Completion (Actual)
June 25, 2018
Study Registration Dates
First Submitted
May 26, 2017
First Submitted That Met QC Criteria
May 26, 2017
First Posted (Actual)
May 31, 2017
Study Record Updates
Last Update Posted (Actual)
July 2, 2019
Last Update Submitted That Met QC Criteria
June 13, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C1091001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g.
protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Group B Streptococcal Infections
-
St George's, University of LondonAssistance Publique - Hôpitaux de Paris; MRC/UVRI and LSHTM Uganda Research... and other collaboratorsRecruitingGroup B Streptococcus Carrier in Childbirth | Group B Streptococcal Infection, Late-Onset | Group B Streptococcal Infection, Early-Onset | Group B Streptococcus Neonatal Sepsis | Group B Strep InfectionFrance, Italy, Malawi, Netherlands, Uganda, United Kingdom
-
St George's, University of LondonMRC/UVRI and LSHTM Uganda Research Unit; MU-JHU CAREActive, not recruitingGroup B Streptococcus Carrier in Childbirth | Group B Streptococcal Infection, Late-Onset | Group B Streptococcal Infection, Early-Onset | Group B Streptococcus Neonatal Sepsis | Group B Strep InfectionUganda
-
St George's, University of LondonMRC/UVRI and LSHTM Uganda Research Unit; MU-JHU CARECompletedGroup B Streptococcus Carrier in Childbirth | Group B Streptococcal Infection, Late-Onset | Group B Streptococcal Infection, Early-Onset | Group B Streptococcus Neonatal Sepsis | Group B Strep InfectionUganda
-
Health Science Center of Xi'an Jiaotong UniversityGuangzhou Women and Children's Medical CenterUnknownInvasive Group B Streptococcal DiseaseChina
-
Minervax ApSLarix A/SCompletedGroup B Streptococcal InfectionDenmark, United Kingdom, South Africa
-
Minervax ApSIqvia Pty LtdActive, not recruitingGroup B Streptococcal InfectionsBelgium
-
PfizerCompletedGroup B Streptococcal InfectionsUnited States
-
University of OxfordImperial College London; Public Health EnglandUnknownInvasive Streptococcal Infection | Invasive Group A Streptococcal Disease | Invasive Group B Streptococcal Disease | Necrotising FasciitisUnited Kingdom
-
Fayoum University HospitalWithdrawnGroup B Streptococcal InfectionEgypt
-
Ryerson UniversityChr HansenCompletedGroup B Streptococcal InfectionCanada
Clinical Trials on Multivalent group B streptococcus vaccine
-
PfizerCompletedGroup B Streptococcus InfectionsUnited States, South Africa, United Kingdom
-
PfizerCompletedGroup B Streptococcus InfectionsUnited States
-
Novartis VaccinesCompletedStreptococcal InfectionsSouth Africa
-
Novartis VaccinesCompletedBacterial Infections | Streptococcal Infections | Gram-Positive Bacterial InfectionsSouth Africa, Malawi
-
Novartis VaccinesCompletedGroup B Streptococcus (GBS) DiseaseSwitzerland
-
NovartisNovartis VaccinesCompletedA Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS VaccineGroup B Streptococcus (GBS) DiseaseSwitzerland
-
Novartis VaccinesGlaxoSmithKlineCompletedGroup B StreptococcusBelgium
-
NovartisNovartis VaccinesCompletedBacterial Infection | Streptococcal Infection | Gram-positive Bacterial InfectionBelgium, Canada
-
Fayoum University HospitalWithdrawnGroup B Streptococcal InfectionEgypt
-
PfizerActive, not recruiting